The insulin-like growth factor pathway as a target for cancer therapy
详细信息 查看全文
- 作者：Iker López-Calderero (1)
Elizabeth Sánchez Chávez (1)
Rocío García-Carbonero (1) - 关键词：IGF ; 1 pathway ; Review ; Anticancer therapy ; Monoclonal antibodies ; Tyrosine kinase inhibitors
- 刊名：Clinical and Translational Oncology
- 出版年：2010
- 出版时间：May 2010
- 年：2010
- 卷：12
- 期：5
- 页码：326-338
- 全文大小：702KB
- 参考文献：1. Tao Y, Pinzi V, Bourhis J et al (2007) Mechanisms of Disease: signalling of the insulin-like growth factor 1 receptor pathway—therapeutic perspectives in cancer. Natur Rev Clin Pract Oncol 4:591-02 CrossRef
2. M. Pollak (2008) Targeting insulin and insulinlike growth factor signalling in oncology. Curr Opin Pharmacol 8:384-92 CrossRef
3. Lelbach A, Muzes G, Feher J (2005) The insulinlike growth factor system: IGFs, IGF-binding proteins and IGFBP-proteases. Acta Physiol Hung 92:97-07 CrossRef
4. Froesch ER, Burgi H, Ramseiser EB et al (1963) Antibody-suppressible and nonsuppressible insulin- like activities in human serum and their physiologic significance. J Clin Invest 42:1816-834 CrossRef
5. Pavelic J, Matijevic T, Knezevic J (2007) Biological and physiological aspects of action of insulinlike growth factor peptide family. Indian J Med Res 125:511-22
6. Gauguin L, Klaproth B, Sajid W et al (2008) Structural basis for the lower affinity of the insulin- like growth factors for the insulin receptor. J Biol Chem 283:2604-613 CrossRef
7. Benyoucef S, Surinya KH, Hadaschik D et al (2007) Characterization of insulin/IGF hybrid receptors: contributions of the insulin receptor L2 and Fn1 domains and the alternatively spliced exon 11 sequence to ligand binding and receptor activation. Biochem J 403:603-13 CrossRef
8. Kornfeld S (1992) Structure and function of the mannose-6-phosphate/insulin like growth factor II receptors. Annu Rev Biochem 61:307-30 CrossRef
9. Belfiore A (2007) The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer. Curr Pharm Des 13:671-86 CrossRef
10. Clemmons DR (2001) Use of mutagenesis to probe IGF-binding protein structure/function relationships. Endocr Rev 22:800-17 CrossRef
11. Buckbinder L, Talbott R, Velasco-Miguel S et al (1995) Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 377:646-49 CrossRef
12. De Meyts P, Whittaker J (2002) Structural biology of insulin and IGF-1 receptors: implications for drug design. Nat Rev Drug Discov 1:769-83 CrossRef
13. Kooijman R, Lauf JJ, Kappers AC et al (1995) Insulin- like growth factor induces phosphorylation of immunoreactive insulin receptor substrate and its association with phosphatidylinositol-3 kinase in human thymocytes. J Exp Med 182:593-97 CrossRef
14. Shaw RJ and Cantley LC (2006) Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441:424-30 CrossRef
15. Paz-Ares L, Blanco-Aparicio C, García-Carbonero R, Carnero A (2009) Inhibiting PI3K as a therapeutic strategy against cancer. Clin Transl Oncol 11:572-79 CrossRef
16. Ma J, Pollak M, Giovannucci E et al (1999) Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I, and IGF-binding protein-3. J Natl Cancer Inst 91:620-25 CrossRef
17. Chan JM, Stampfer MJ, Giovannucci E et al (1998) Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279:563-66 CrossRef
18. Cheng I et al (2006) Common genetic variation in IGF1 and prostate cancer risk in the Multiethnic Cohort. J Natl Cancer Inst 98:123-34
19. Tsuchiya N et al (2006) Impact of IGF-I and CYP19 gene polymorphisms on the survival of patients with metastatic prostate cancer. J Clin Oncol 24:1982-989 CrossRef
20. Giovannucci E, Ascherio A, Rimm EB et al (1995) Physical activity, obesity, and risk for colon cancer and adenoma in men. Ann Intern Med 122:327-34
21. Calle EE, Rodriguez C, Walker-Thurmond K et al (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348:1625-638 CrossRef
22. Wolpin BM, Meyerhardt JA, Chan AT et al (2009). Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer. J Clin Oncol 27:176-85 CrossRef
23. Ahlgren M, Melbye M, Wohlfahrt J, Sorensen TI (2004) Growth patterns and the risk of breast cancer in women. N Engl J Med 351:1619-626 CrossRef
24. Osborne, CK, Bolan G, Monaco ME et al (1976) Hormone responsive human breast cancer in longterm tissue culture: effect of insulin. Proc Natl Acad Sci USA 73:4536-540 CrossRef
25. Heuson JC, Legros N (1972) Influence of insulin deprivation on growth of the 7,12-dimethylbenz(a) anthracene-induced mammary carcinoma in rats subjected to alloxan diabetes and food restriction. Cancer Res 32:226-32
26. Myal Y, Shiu RP, Bhaumick B (1984) Receptor binding and growth-promoting activity of insulinlike growth factors in human breast cancer cells (T-47D) in culture. Cancer Res 44:5486-490
27. Frasca F, Pandini G, Sciacca L et al (2008) The role of insulin receptors and IGF-I receptors in cancer and other diseases. Arch Physiol Biochem 114:23-7 CrossRef
28. Kaneda A, Wang CJ, Cheong R et al (2007) Enhanced sensitivity to IGF-II signalling links loss of imprinting of IGF2 to increased cell proliferation and tumor risk. Proc Natl Acad Sci USA 104: 20926-0931 CrossRef
29. DiGiovanni J, Kiguchi K, Frijhoff A et al (2000) Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice. Proc Natl Acad Sci USA 97:3455-460 CrossRef
30. Wu Y, Cui K, Miyoshi K et al (2003). Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors. Cancer Res 63:4384-388
31. Majeed N, Blouin MJ, Kaplan-Lefko PJ et al (2005). A germ line mutation that delays prostate cancer progression and prolongs survival in a murine prostate cancer model. Oncogene 24:4736-740 CrossRef
32. Hadsell DL, Murphy KL, Bonnette SG et al (2000) Cooperative interaction between mutant p53 and des(1-)IGF-I accelerates mammary tumorigenesis. Oncogene 19:889-98 CrossRef
33. Carboni JM, Lee AV, Hadsell DL et al (2005) Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor. Cancer Res 65:3781-787 CrossRef
34. Sell C, Rubini M, Rubin R et al (1993) Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc Natl Acad Sci USA 90:11217-1221 CrossRef
35. Martin MJ, Melnyk N, Pollard M et al (2006) The insulin-like growth factor I receptor is required for Akt activation and suppression of anoikis in cells transformed by the ETV6-NTRK3 chimeric tyrosine kinase. Mol Cell Biol 26:1754-769 CrossRef
36. Wiseman LR, Johnson MD, Wakeling AE et al (1993) Type I IGF receptor and acquired tamoxifen resistance in oestrogen-responsive human breast cancer cells. Eur J Cancer 29A:2256-264 CrossRef
37. Lu Y, Zi X, Zhao Y et al (2001) Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 93:1852-857 CrossRef
38. Kuribayashi A, Kataoka K, Kurabayashi T, Miura M (2004) Evidence that basal activity, but not transactivation, of the epidermal growth factor receptor tyrosine kinase is required for insulin-like growth factor I-induced activation of extracellular signal-regulated kinase in oral carcinoma cells. Endocrinology 145:4976-984 CrossRef
39. Zhang Q, Thomas SM, Lui VW et al (2006) Phosphorylation of TNF-alpha converting enzyme by gastrin-releasing peptide induces amphiregulin release and EGF receptor activation. Proc Natl Acad Sci U S A 103:6901-906 CrossRef
40. Morgillo F, Woo JK, Kim ES et al (2006) Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res 66:10:100-1
41. Ueda S et al (2006) Potential crosstalk between insulin-like growth factor receptor type 1 and epidermal growth factor receptor in progression and metastasis of pancreatic cancer. Mod Pathol 19:788-96
42. Lu Y, Zi X, Zhao Y et al (2001) Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 93:1852-857 CrossRef
43. Nahta R, Yuan LX, Zhang B et al (2005) Insulinlike growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 65:11118-1128 CrossRef
44. Chakraborty AK, Liang K, DiGiovanna MP (2008) Co-targeting insulin-like growth factor I receptor and HER2: dramatic effects of HER2 inhibitors on nonoverexpressing breast cancer. Cancer Res 68:1538-545 CrossRef
45. Harris LN, You F, Schnitt SJ et al (2007) Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res13:1198-207 CrossRef
46. Wu JD, Haugk K, Woodke L et al (2006) Interaction of IGF signaling and the androgen receptor in prostate cancer progression. J Cell Biochem 99:392-40 CrossRef
47. Lin HK, Yeh S, Kang HY, Chang C (2001) Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor. Proc Natl Acad Sci USA 98:7200-205 CrossRef
48. Stephen RL, Shaw LE, Larsen C et al (2001) Insulin-like growth factor receptor levels are regulated by cell density and by long term estrogen deprivation in MCF7 human breast cancer cells. J Biol Chem 276:40080-0086 CrossRef
49. Martin LA, Pancholi S, Chan CM et al (2005) The anti-oestrogen ICI 182,780, but not tamoxifen, inhibits the growth of MCF-7 breast cancer cells refractory to long-term oestrogen deprivation through down-regulation of oestrogen receptor and IGF signalling. Endocr Relat Cancer 12:1017-036 CrossRef
50. Campbell RA, Bhat-Nakshatri P, Patel NM et al (2001) Phosphatidylinositol 3-kinase/AKTmediated activation of estrogen receptor alpha: a new model for antiestrogen resistance. J Biol Chem 276:9817-824 CrossRef
51. Helle SI, Holly JM, Tally M et al (1996) Influence of treatment with tamoxifen and change in tumor burden on the IGF-system in breast cancer patients. Int J Cancer 69:335-39 CrossRef
52. Slomiany MG, Black LA, Kibbey MM et al (2006) IGF-1 induced vascular endothelial growth factor secretion in head and neck squamous cell carcinoma. Biochem Biophys Res Commun 342:851-58 CrossRef
53. Li J et al (2005) Upregulation of VEGF-C by androgen depletion: the involvement of IGF-IRFOXO pathway. Oncogene 24:5510-520 CrossRef
54. Tang Y et al (2003) Vascular endothelial growth factor C expression and lymph node metastasis are regulated by the type I insulin-like growth factor receptor. Cancer Res 63:1166-171
55. Slomiany MG, Rosenzweig SA (2006) Hypoxiainducible factor-1-dependent and -independent regulation of insulin-like growth factor-1-stimulated vascular endothelial growth factor secretion. J Pharmacol Exp Ther 318:666-75 CrossRef
56. Stearns M et al (2005) Activated Ras enhances insulin-like growth factor I induction of vascular endothelial growth factor in prostate epithelial cells. Cancer Res 65:2085-088 CrossRef
57. Burroughs KD et al (2003) Phosphatidylinositol 3-kinase and mek1/2 are necessary for insulinlike growth factor-I-induced vascular endothelial growth factor synthesis in prostate epithelial cells: a role for hypoxia-inducible factor-1? Mol Cancer Res 1:312-22
58. Lacy MQ, Alsina M, Fonseca R et al (2008) Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. J Clin Oncol 26:3196-03 CrossRef
59. Haluska P, Shaw HM, Batzel GN et al (2007) Phase I dose escalation study of the anti insulinlike growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res 13:5834-840 CrossRef
60. Haluska P, Worden F, Olmos D et al (2010) Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemother Pharmacol 65:765-73 CrossRef
61. Olmos D, Postel-Vinay S, Molife LR et al (2010) Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing’s sarcoma: a phase 1 expansion cohort study. Lancet Oncol 11:129-35 CrossRef
62. Attard G, Fong PC, Molife R et al (2006). Phase I trial involving the pharmacodynamic (PD) study of circulating tumour cells, of CP-751,871 (C), a monoclonal antibody against the insulinlike growth factor 1 receptor (IGF-1R), with docetaxel (D) in patients (p) with advanced cancer. J Clin Oncol 24:126s
63. Pollak M, Eisenberg P, Karp D et al (2007). Safety and tolerability of the anti-IGF-I receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in patients with advanced solid tumors. AACR Meeting Abstracts (abstract LB-343)
64. Karp DD, Paz-Ares LG, Novello S et al (2009) Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol 27:2516-522 CrossRef
65. Higano CS Yu EY, Whiting SH et al (2007) A phase I, first in man study of weekly IMC-A12, a fully human insulin like growth factor-I receptor IgG1 monoclonal antibody, in patients with advanced solid tumors. J Clin Oncol 25 ASCO Annual Meeting Proceedings Abstr 3505
66. Malempati S, Weigel B, Ingle AM et al (2009) A phase I trial and pharmacokinetic study of IMC-A12 in pediatric patients with relapsed/ refractory solid tumors: A Children’s Oncology Group Phase I Consortium study. ASCO Annual Meeting. J Clin Oncol 27:15s (abstr 10013) CrossRef
67. Higano C, Alumkal J, Ryan CJ et al (2009) A phase II study evaluating the efficacy and safety of single agent IMC-A12, a monoclonal antibody (MAb), against the insulin-like growth factor-1 receptor ( IGF-IR), as monotherapy in patient with metastatic, asymptomatic castration-resistant prostate cancer (CRCP). ASCO Annual Meeting. J Clin Oncol 27:15s (abstr 5142) CrossRef
68. Tolcher AW, Sarantopoulos J, Patnaik A et al (2009) A phase I pharmacokinetic and pharmacodynamic study of AMG 479, a fully human monoclonal antibody against insulin-like growth factor receptor 1. J Clin Oncol 27:5800-807 CrossRef
69. Sarantopoulos J, Mita AC, Mulay M et al (2008) A phase IB study of AMG 479, a type 1 insulinlike growth factor receptor (IGF1R) antibody, in combination with panitumumab (P) or gemcitabine (G). J Clin Oncol 26:173s
70. Atzori, F, Tabernero J, Cervantes A et al (2008) A phase I, pharmacokinetic and pharmacodynamic study of weekly MK-0646, and insulinlike growth factor-1 receptor monoclonal antibody in patients with advanced solid tumors. J Clin Oncol 26:157s CrossRef
71. Hidalgo M, Tirado Gomez M, Lewis N et al (2008) A phase I study of MK-0646, a humanized monoclonal antibody against the insulinlike growth factor receptor type 1 in advanced solid tumor patients in a q2 wk schedule. J Clin Oncol 26:158s
72. Javle M, Varadhachary G, Bhosale P et al (2010) Phase I study of MK-0646, a humanized monoclonal antibody against IGF-1R in combination with gemcitabine or gemcitabine plus erlotinib for advanced previously untreated pancreatic cancer. ASCO Gastrointestinal Cancers Symposium (abstract 131)
73. Moreau P, Hulin C, Facon T et al (2007) Phase I study of AVE1642 anti IGF-1R monoclonal antibody in patients with advanced multiple myeloma. ASH Meeting (abstr 1166)
74. Tolcher AW, Rothenberg ML, Rodon J et al (2008) A phase I study of AVE1642, a humanized monoclonal antibody IGF-1R antagonist, in patients with advanced solid tumor. J Clin Oncol 26:173s CrossRef
75. Rodon J, Patnaik A, Stein M et al (2007) A phase I study of q3W R1507, a human monoclonal antibody IGF-1R antagonist in patients with advanced cancer. J Clin Oncol 25:160s
76. Leong S, Gore L, Benjamin R et al (2007) A phase I study of R1507, a human monoclonal antibody IGF-1R (insulin-like growth factor receptor) antagonist given weekly in patients with advanced solid tumors. AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting
77. Patel S, Pappo A, Crowley J et al (2009) A SARC global collaborative phase II trial of R1507, a recombinant human monoclonal anti body to the insulin-like growth factor-1 receptor (IGF1R) in patients with recurrent or refractory sarcomas. ASCO Annual Meeting. J Clin Oncol 27: 15s (abstr 10503) CrossRef
78. Seraj J, Tsai M, Seiberling M et al (2007). Evaluation of safety and pharmacokinetics of a fully human IGF-1 receptor antibody, SCH 717454, in healthy volunteers. AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting
79. Ryan CJ, Harzstark AH (2008) A pilot doseescalation study of the effects of nordihydroguaiaretic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer. BJU Int 101:436-39 CrossRef
80. Lindsay CR, Chan E, Evans TR et al (2009). Phase I dose escalation study of continuous oral dosing of OSI-906, an insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase inhibitor, in patients with advanced solid tumors. J Clin Oncol 27:15s CrossRef
81. Carden CP, Frentzas S, Langham M et al (2009) Preliminary activity in adrenocortical tumor in phase I dose escalation study of intermittent oral dosing of OSI-906, a small molecule insulinlike growth factor-1 receptor tyrosine kinase inhibitor in patients with advanced solid tumors. ASCO Annual Meeting. J clin Oncol 27:15s (abstr 3544) CrossRef
82. Britten C, Smith D, Bui L et al (2008) A phase I dose de-escalation study of XL228, a potent IGFIR/src inhibitor in patients with advanced malignancies. EORTCNCI-AACR symposium on Molecular Targets and Cancer Therapeutics Congress
83. Cortes J, Paquette R, Talpaz M et al (2008) Preliminary clinical activity in a phase I trial of the BCR-ABL/IGF-1R/aurora kinase inhibitor XL228 in patients with Ph+ leukemias with either failure to multiple TKI therapies or with T315I mutation. ASH Annual Meeting
84. Yin D, Paccagnella M, Lacy M et al (2008) Population pharmacokinetics of CP-751,871, a monoclonal antibody against IGF-1 receptor, in patients with multiple myeloma or solid tumors. ASCO Annual Meeting. J Clin Oncol 26 (abstr 2524)
85. Gualberto A, Dolled-Filhart P, Hixon M et al (2009) Molecular bases for sensitivity to figitumumab (CP-751,871) in NSCLC. ASCO Annual Meeting. J Clin Oncol 27:15s (abstr 8091) CrossRef - 作者单位：Iker López-Calderero (1)
Elizabeth Sánchez Chávez (1)
Rocío García-Carbonero (1)
1. Department of Medical Oncology, Hospital Universitario Virgen del Rocío Instituto de Biomedicina de Sevilla (IBIS), Avenida Manuel Siurot, s/n, ES-41013, Sevilla, Spain
文摘
The insulin-like growth factor (IGF) system is emerging as a promising new target in cancer therapy. Experimental models and epidemiological studies have demonstrated that the IGF system plays a key role in malignant transformation and cancer progression. Different strategies are being pursued to target this pathway. Several monoclonal antibodies and tyrosine kinase inhibitors targeting the IGF-1 receptor are in clinical development. Early clinical trials indicate these drugs have acceptable safety profiles, and there is pharmacodynamic evidence that actual target inhibition is achievable in patients. Emerging efficacy data as single agent and in combination with chemotherapy is encouraging yet too early for firm conclusions. This manuscript reviews the role of the IGF system in human malignancy and its interactions with other signaling pathways, and summarizes the available data of IGF-1R inhibitors currently in clinical trials.